At the recent ESMO Congress 2024 in Barcelona, researchers presented early-phase trial results for several novel targeted therapies that may one day expand treatment options for various types of cancer.
MTAP Deletion
A new drug called AMG193 showed promising results in patients with tumors that have a specific genetic deletion called MTAP. This deletion occurs in about 15% of cancers. The drug was well-tolerated and showed effectiveness in lung, pancreatic, and biliary tract cancers.
KRAS G12D Mutation
Another breakthrough involves a drug called ASP3082, which targets the KRAS G12D mutation. This mutation is common in pancreatic, colorectal, and lung cancers. Early results showed good safety and effectiveness, particularly in difficult-to-treat pancreatic cancer.
CDK2 and CDK4/6
Two studies focused on targeting proteins called CDK2 and CDK4/6, which are involved in cancer cell growth. These new approaches could help patients with breast cancer who have developed resistance to current treatments.
A drug called INCB123667, which selectively targets CDK2, showed encouraging results in patients with advanced solid tumors, particularly ovarian cancer.
While these therapies are still in early stages of testing, they represent significant progress in the field of precision oncology. As research continues, these new targeted treatments may offer more personalized and effective options for cancer patients in the future.
More Reading:
- Tissue Agnostic Targeted Therapy
- Advances in Genomic-Molecular Testing What You Need to Know
- What is a Liquid Biopsy?
Connect With Others for Support and information
Cancer Connect was the first social network created for people with cancer. Founded by oncologists to support cancer patients and their caregivers, over 40 million individuals have accessed Cancer Connect programs since 1997. Cancer Connect is used by leading cancer centers like Dana Farber and Roswell Park to support their patients. Join the conversation, ask questions, share your experience, and learn how the best cancer centers are treating cancer from others. Share your experience, ask a question, or start a conversation by posting on Cancer Connect.
References:
1. Simonelli M, et al. Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (Pts) with advanced solid tumors: A phase I Study. ESMO Congress 2024, Abstract 617MO.
2. Yap TA, et al. Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors. ESMO Congress 2024, Abstract 618MO.
3. Park W, et al. Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). ESMO Congress 2024, Abstract 608O.
4. Sacher AG, et al. Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors. ESMO Congress 2024, Abstract 604O.
